A high-dose, double-blind study of ceruletide in the treatment of schizophrenia.
Ceruletide, a cholecystokinin analogue, has been reported to interact with dopamine in the CNS and to benefit schizophrenic individuals. The authors, using a double-blind design, a higher total dose, and a larger sample size than previous studies, found no evidence of benefit.
D000328:Adult; D002108:Ceruletide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D010919:Placebos; D002108:Ceruletide